| Description | Lusutrombopag (Mulpleta) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. |
| In vitro | Lusutrombopag is an agonist of the thrombopoietin receptor that activates platelet production. Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels. |
| Synonyms | 芦曲泊帕, 鲁索曲波帕, S-888711, Mulpleta |
| molecular weight | 591.55 |
| Molecular formula | C29H32Cl2N2O5S |
| CAS | 1110766-97-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 30 mg/mL (50.72 mM) |
| References | 1. Kim ES, et al. Lusutrombopag: First Global Approval. Drugs. 2016 Jan;76(1):155-8. |